Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 11/20 | 0.66 |
| ▸ | TACR3 | P29371 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 4/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | RHOC | P08134 | 1/20 | 0.44 |
| ▸ | RHOA | P61586 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7684256 | 0.92 | TACR1 (0.55) | TACR1TACR3USP2RHOCRHOA | |
| SCHEMBL4983555 | 0.89 | TACR1 (0.62) | TACR1TACR3USP2MITFRHOC | |
| SCHEMBL4987212 | 0.87 | TACR1 (0.49) | TACR1TACR3USP2RHOCRHOA | |
| SCHEMBL7688875 | 0.86 | TACR1 (0.49) | TACR1TACR3USP2RHOCRHOA | |
| SCHEMBL4987525 | 0.86 | TACR1 (0.48) | TACR1TACR3USP2RHOCRHOA | |
| SCHEMBL14217474 | 0.85 | TACR1 (0.61) | TACR1TACR3USP2MITFRHOC | |
| SCHEMBL12809194 | 0.85 | OPRK1 (0.52) | TACR1TACR3RHOCRHOA | |
| SCHEMBL4991943 | 0.83 | TACR1 (0.59) | TACR1TACR3ABCB1 | |
| SCHEMBL7864817 | 0.83 | TACR1 (0.48) | TACR1 | |
| SCHEMBL13818183 | 0.83 | TACR1 (0.58) | TACR1TACR3USP2MITFRHOC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604200-B2 | Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-12-10 | — | — | US | disclosed |
| US-8138334-B2 | Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-8138334-B2 | Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-8138334-B2 | Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| EP-1581518-B1 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| EP-1581518-B1 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| US-20100292228-A1 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292228-A1 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292228-A1 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-18 | — | — | US | disclosed |
| US-7795261-B2 | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-6110939-A | AS A SUBSTANCE P ANTAGONISTS TREATING TACHYKININ-MEDIATED DISEASE, ASTHMA, CENTRAL NERVOUS SYSTEM DISORDER | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-08-29 | — | — | US | disclosed |
| EP-0862566-B1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2000-01-12 | — | — | EP | disclosed |
| EP-0869955-A1 | N-ACYL-2-SUBSTITUTED-4-(BENZIMIDAZOLYL- OR IMIDAZOPYRIDINYL-SUBSTITUTED RESIDUES)-PIPERIDINES AS TACHYKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-10-14 | — | — | EP | disclosed |
| EP-0862566-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-09-09 | — | — | EP | disclosed |
| EP-0855999-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-08-05 | — | — | EP | disclosed |
| EP-0843679-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-(FUSED IMIDAZOLE)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997024324-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024350-A1 | N-ACYL-2-SUBSTITUTED-4-(BENZIMIDAZOLYL- OR IMIDAZOPYRIDINYL-SUBSTITUTED RESIDUES)-PIPERIDINES AS TACHYKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024356-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-(FUSED IMIDAZOLE)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997016440-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292228-A1 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | NPSR1, OPRK1, PROKR2 | TACR1 79/4885TACR3 189/4885USP2 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.